Examples of using Dronedarone in English and their translations into Polish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
bepridil, dronedarone, encainide, flecainide,
Concomitant administration of Kaletra and amiodarone or dronedarone is contraindicated(see section 4.3)
Dronedarone has no significant potential to inhibit CYP 1A2,
The in vitro plasma protein binding of dronedarone and its N-debutyl metabolite is 99.7%
Monitoring of their plasma concentrations and appropriate dose adjustment is recommended in case of coadministration with dronedarone.
The most frequent adverse reactions observed with dronedarone 400 mg twice daily in the 5 studies were diarrhoea,
There was a weak interaction between dronedarone and atorvastatin which resulted in a mean 1.7-fold increase in atorvastatin exposure.
When dabigatran etexilate 150 mg once daily was co-administered with dronedarone 400 mg twice daily,
There was a weak interaction between dronedarone and statins transported by OATP,
Dronedarone had no genotoxic effects, based on one in vivo micronucleus test in mice and four in vitro tests.
terfenadine, dronedarone, saquinavir.
did not interact significantly on dronedarone pharmacokinetics.
itraconazole and dronedarone see section 4.3.
exhibits pharmacodynamic activity but is 3 to 10-times less potent than dronedarone.
Dronedarone and amiodarone(medicines used to control the heartbeat)
It is predicted that dronedarone could also increase the exposure of lovastatin within the same range as simvastatin acid.
Consequently, INR should be closely monitored after initiating dronedarone in patients taking vitamin K antagonists as per their label.
acetylsalicylic acid) dronedarone, a medicine to treat abnormal heart beat.
International Normalised Ratio(INR) should be closely monitored after initiating dronedarone in patients taking vitamin K antagonists as per their label.
verapamil, dronedarone and amiodarone is not recommended see sections 4.5 and 5.2.